Q2 2026 ADMA Biologics Inc Earnings Call Transcript
Key Points
- ADMA Biologics Inc (ADMA) reported strong second-quarter results with total revenue of $124.4 million, a 2% year-over-year increase, and gross margin expanding significantly to 69% from 55% in the prior-year period.
- Ascentiv revenue grew 24% year-over-year to $102.9 million, with June delivering the strongest sequential month-over-month end-user utilization growth since the first half of 2024, driven by increasing physician adoption and new patient starts.
- The company generated strong cash flow with $30 million in operating cash flow during the quarter, ending with $136 million in cash and maintaining a net leverage of less than half a turn, providing substantial financial flexibility.
- ADMA Biologics Inc (ADMA) is actively returning capital to shareholders, having repurchased approximately 13.8 million shares year-to-date (about 5.3% of outstanding stock) and remains on track to complete its $200 million or more 2026 share repurchase target.
- The company submitted a new abstract for the 2026 ACAAI meeting showing statistically significant reductions in infection-related hospitalizations, outpatient utilization, and antibiotic use in 127 medically complex PI patients after switching to Ascentiv, strengthening its real-world evidence base.
- ADMA Biologics Inc (ADMA) reiterated its full-year 2026 guidance for revenue of $530-$560 million and adjusted EBITDA of $265-$300 million, expressing confidence in meeting or exceeding expectations.
- The pipeline candidate SG001 is progressing on track, with planned cGMP conformant lot production in H2 2026 and a pre-IND meeting package submission to the FDA by year-end, representing a potential $300-$500 million annual revenue opportunity.
- ADMA Biologics Inc (ADMA) continues to face significant competitive pressures in the US standard immunoglobulin market, including increased supply and aggressive discounting and rebating from competitors.
- Bivigam revenue declined substantially year-over-year to $19.4 million, and while it stabilized sequentially, management still anticipates it to be down 40-50% from 2025 levels for the full year.
- The company's effective tax rate increased to 24.7% in the quarter, up approximately 10 percentage points year-over-year due to discrete tax benefits recognized in the prior-year period, impacting net income growth.
- Accounts receivable DSOs remain elevated at approximately 101 days, though improving from 107 days in Q1, and the company targets maintaining DSOs between 90-105 days in the second half of 2026.
- R&D expenses are expected to step up in the coming quarters as the company prepares for SG001's potential future clinical trial and conformance lot manufacturing, which could pressure near-term profitability.
- The company's guidance assumes sustained competitive dynamics and pricing pressure in the standard IG market through the balance of the year, reflecting a conservative outlook despite improving commercial indicators.
- While Ascentiv is growing, the overall IG portfolio faces headwinds from market dislocation, and management noted that Bivigam remains substantially down year-over-year despite stabilization efforts.
Good afternoon and welcome to the ADMA Biologics second quarter 2026 financial results and business update conference call on Wednesday, August 5, 2026. (Operator Instructions) Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the end of the call.
At this time, I would like to introduce the company. Please go ahead.
Welcome, everyone, and thank you for joining us this afternoon to discuss ADMA Biologics' financial results for the second quarter of 2026 and recent corporate updates. I'm joined today by Adam Grossman, our President; and Chief Executive Officer Terry Kohler, our Chief Financial Officer and Treasurer.
During today's call, Adam will provide some introductory comments and provide an update on corporate progress, and Terry will provide an overview of the company's second quarter 2026 financial results. Finally, Adam will then provide some brief summary remarks before opening up the call for questions.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
